Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 8/20 | 0.42 |
| ▸ | GNAO1 | P09471 | 8/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 8/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 3/20 | 0.38 |
| ▸ | CES1 | P23141 | 3/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16133075 | 0.86 | ABL1 (0.40) | ABL1RIN1 | |
| SCHEMBL14215879 | 0.80 | CES2 (0.52) | CES2CES1NAAAMEN1KMT2A | |
| SCHEMBL20382507 | 0.80 | CES2 (0.52) | CES2CES1NAAAMEN1KMT2A | |
| SCHEMBL4911800 | 0.80 | CES2 (0.52) | CES2CES1NAAAMEN1KMT2A | |
| SCHEMBL14215972 | 0.80 | CES2 (0.52) | CES2CES1NAAAMEN1KMT2A | |
| SCHEMBL3885339 | 0.80 | CES2 (0.52) | CES2CES1NAAAMEN1KMT2A | |
| SCHEMBL6571414 | 0.80 | CES2 (0.52) | CES2CES1NAAAMEN1KMT2A | |
| SCHEMBL17713632 | 0.79 | HSD11B1 (0.40) | ABL1RIN1MEN1KMT2A | |
| SCHEMBL6141447 | 0.78 | CES2 (0.50) | ABL1RIN1CES2CES1MEN1 | |
| SCHEMBL21709794 | 0.78 | HSD11B1 (0.44) | CES2CES1NAAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11208655-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200115709-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11208655-B2 | Functionally-modified oligonucleotides and subunits thereof | RTCB, NSUN3, NSUN2 | ABL1 4253/4885RIN1 1802/4885GNAI3 1942/4885 |
| US-20200115709-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | RTCB, NSUN3, NSUN2 | ABL1 4253/4885RIN1 1802/4885GNAI3 1942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.